INMB · INmune Bio, Inc.

This amended and restated agreement marks a strategic escalation in INmune Bio’s relationship with Anthony Nolan, transforming the Company from a non-party beneficiary to a directly bound, financially liable participant in the CORDStrom™ supply chain. By assuming joint and several liability for royalties and fees, INmune Bio has elevated its commitment to the platform’s commercial viability — a material shift from prior arrangements where only its UK subsidiary IMB bore those obligations. The 2% royalty on net sales, though modest in rate, carries real financial weight due to the £5M annual cap and its linkage to future product revenue — making it a direct earnings-sensitive obligation once commercialization begins. The CPI-adjusted per-cord fee introduces predictable but escalating cost pressure tied to UK inflation, reinforcing long-term budgeting considerations. Critically, the agreement secures not just volume but quality: the explicit mandate for GMP and HTA compliance, coupled with defined Materials Acceptance Criteria (e.g., neonatal weight and maternal age specifications), positions CORDStrom™ for regulatory acceptance across FDA, EMA, and MHRA jurisdictions. The 10-year term post-First Commercial Sale provides stability for platform development, while the asymmetric termination windows — 30 days for INmune Bio versus 6 months for Anthony Nolan — reflect negotiated leverage favoring the Company’s operational agility. Management’s commentary in Exhibit 99.1 underscores that this is not merely a supply deal but a foundational enabler for solving the industry-wide MSC consistency challenge, directly supporting clinical programs in RDEB, oncology, and inflammatory diseases — all of which are highlighted as near-term value inflection points.